Italia markets open in 5 hours 14 minutes

Almirall, S.A. (0O9B.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
10,34-0,14 (-1,34%)
Alla chiusura: 04:53PM GMT

Almirall, S.A.

Ronda General Mitre, 151
Barcelona 08022
Spain
34 93 291 30 00
https://www.almirall.com

Settore/i
Settore
Impiegati a tempo pieno1.904

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Carlos Gallardo PiquéCEO, President, Member of Management Board & Chairman of the Board50kN/D1972
Mr. Michael McClellanCFO & Member of Management BoardN/DN/D1972
Mr. Eloi Crespo CerveraChief Industrial Operations Officer & Member of Management BoardN/DN/DN/D
Mr. Esteve Conesa PanicotChief People & Culture Officer and Member of Management BoardN/DN/DN/D
Dr. Volker KoscielnyChief Medical Officer & Member of Management BoardN/DN/DN/D
Dr. Karl ZiegelbauerChief Scientific Officer & Member of Management BoardN/DN/DN/D
Mr. Paolo CioniniChief Commercial Officer Europe & International and Member of Management BoardN/DN/DN/D
Ms. Isabel GomesChief Legal Officer, General Counsel & Member of Management BoardN/DN/DN/D
Ms. Mercedes Diz LopezChief Marketing Officer & Member of Management BoardN/DN/DN/D
Mr. Pablo Divasson del FraileSenior Director of Investor RelationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2015 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Governance aziendale

L'ISS Governance QualityScore di Almirall, S.A. al 1 marzo 2024 è 4. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 4; diritti degli azionisti: 3; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.